Form 8-K · Current report
Xcel Energy 8-K, filed Oct 30, 2026
- Filed
- CIK
- 0000072903
- Accession no.
- 0001193125-26-441768
Summary
Xcel Energy entered into an equity distribution agreement allowing it to sell up to $6 billion of common stock through at-the-market offerings and forward sale agreements, and terminated its prior at-the-market program. Approximately $448.6 million remained unsold under the prior program, while about $3.8 billion of forward sale agreements under it remain outstanding.
Key points
- Xcel Energy may offer and sell common stock with an aggregate gross sales price of up to $6 billion through sales agents and forward sellers.
- A prior at-the-market equity distribution agreement dated May 1, 2026 was terminated; approximately $448.6 million of common stock remained unsold under it.
- About $3.8 billion of common stock subject to outstanding forward sale agreements from the prior program will remain outstanding after termination.
- The new agreement provides for initially priced forward transactions and collared forward transactions with sales agents and forward purchasers.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 8.01Other Events
- 9.01Financial Statements and Exhibits
From the filing
Item 8.01. Other Events. On October 30, 2026, Xcel Energy Inc. (“Xcel Energy”) entered into an equity distribution agreement (the “Equity Distribution Agreement”) with (i) Barclays Capital Inc., BMO Capital Markets Corp., BNP Paribas Securities Corp., BNY Mellon Capital Markets, LLC, BofA Securities, Inc., BTIG, LLC, CIBC World Markets Corp., Citigroup Global Markets Inc., Goldman Sachs & Co. LLC, Huntington Securities, Inc., Jefferies LLC, J.P. Morgan Securities LLC, KeyBanc Capital Markets Inc., Mizuho Securities USA LLC, Morgan Stanley & Co. LLC, MUFG Securities Americas Inc., Nomura Securities International, Inc. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.